Telix Pharmaceuticals Limited (NASDAQ:TLX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Telix Pharmaceuticals Limited (NASDAQ:TLX) has been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $21.1250.

TLX has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Citigroup boosted their price target on Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Finally, Wall Street Zen raised shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in TLX. Rhumbline Advisers lifted its holdings in Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after buying an additional 1,392 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Telix Pharmaceuticals during the fourth quarter valued at about $89,000. OLD Mission Capital LLC purchased a new stake in shares of Telix Pharmaceuticals during the fourth quarter worth about $111,000. Vident Advisory LLC acquired a new position in shares of Telix Pharmaceuticals in the fourth quarter worth about $204,000. Finally, IHT Wealth Management LLC acquired a new position in shares of Telix Pharmaceuticals in the second quarter worth about $213,000.

Telix Pharmaceuticals Stock Performance

Shares of TLX stock opened at $7.72 on Thursday. The company’s fifty day simple moving average is $7.31 and its 200-day simple moving average is $8.86. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $20.00. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27.

Telix Pharmaceuticals (NASDAQ:TLX) last announced its quarterly earnings results on Friday, February 20th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). On average, equities research analysts expect that Telix Pharmaceuticals will post 0.24 earnings per share for the current year.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.